GLP-1 Content

Glucagon-like peptide-1 receptor agonists (GLP-1s), like Ozempic and Victoza, are medications originally developed to manage diabetes. In the last few years, they have gained popularity in the treatment of obesity.

With their growing prevalence, there is a great demand for information on this class of medications. The ongoing research on the GLP-1s means more information on these treatments to update consumers and providers.

My experience as a nurse practitioner informs my writing with the knowledge of how the medications work, an ability to understand the new research, and the patient's viewpoint on obesity and obesity-related issues. All of this means I can translate complex information into the content readers are looking for with these treatments.

Sample Article

Content Topics

Medication Information

Ozempic and Wegovy (semaglutides) are only two of this class's growing list of medications. Mounjaro (tirzepatide) is the most recent addition, and more are currently in development. Keep readers informed on the new medications.

New Research

With the medications' growing popularity, investigations to look at the benefits for other health conditions are underway. I can translate new studies into easily understood content for both B2B and B2C clients

Diet and Nutrition

GLP-1s negatively impact appetite. A vital issue for users is ensuring they are eating right. With long-term use of these medications, nutritional content becomes more important.

Obtaining GLP-1s

Acquiring GLP-1 medications requires more than just walking into a pharmacy and purchasing them. I understand the sometimes complicated processes behind acquiring the medications and similar alternatives.

Let me help keep your readers up-to-date on this evolving hot topic

Get started here